Document Detail


Customized versus population approach for evaluation of fetal overgrowth.
MedLine Citation:
PMID:  23147078     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To compare the ability of customized versus normalized population fetal growth norms in identifying neonates at risk for adverse perinatal outcomes (APOs) associated with fetal overgrowth and gestational diabetes (GDM).
STUDY DESIGN: Secondary analysis of a multicenter treatment trial of mild GDM. The primary outcome was a composite of neonatal outcomes associated with fetal overgrowth and GDM. Birth weight percentiles were calculated using ethnicity- and gender-specific population and customized norms (Gardosi).
RESULTS: Two hundred three (9.8%) and 288 (13.8%) neonates were large for gestational age by population (LGApop) and customized (LGAcust) norms, respectively. Both LGApop and LGAcust were associated with the primary outcome and neonatal hyperinsulinemia, but neither was associated with hypoglycemia or hyperbilirubinemia. The ability of customized and population birth weight percentiles for predicting APOs were poor (area under the receiver operating characteristic curve < 0.6 for six of eight APOs).
CONCLUSION: Neither customized nor normalized population norms better identify neonates at risk of APOs related to fetal overgrowth and GDM.
Authors:
Maged M Costantine; Lisa Mele; Mark B Landon; Catherine Y Spong; Susan M Ramin; Brian Casey; Ronald J Wapner; Michael W Varner; Dwight J Rouse; John M Thorp; Anthony Sciscione; Patrick Catalano; Steve N Caritis; Yoram Sorokin; Alan M Peaceman; Jorge E Tolosa; Garland D Anderson;
Related Documents :
9096898 - Fetal encephalopathy after maternal anaphylaxis. case report.
2022458 - Pre- to postnatal reduction in ultrasound attenuation coefficient of the liver.
8915088 - The significance of non-visualization of the fetal bladder during an ultrasound examina...
7973788 - Diagnosis and treatment of structural fetal cardiac abnormality and dysrhythmia.
3523328 - Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia.
9240858 - Maternal clinical factors influencing hiv-1 transmission.
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural     Date:  2012-11-12
Journal Detail:
Title:  American journal of perinatology     Volume:  30     ISSN:  1098-8785     ISO Abbreviation:  Am J Perinatol     Publication Date:  2013 Aug 
Date Detail:
Created Date:  2013-07-16     Completed Date:  2013-12-11     Revised Date:  2014-03-19    
Medline Journal Info:
Nlm Unique ID:  8405212     Medline TA:  Am J Perinatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  565-72     Citation Subset:  IM    
Copyright Information:
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Area Under Curve
Birth Weight*
Blood Glucose
C-Peptide / blood
Confidence Intervals
Diabetes, Gestational* / blood
Female
Fetal Macrosomia* / blood
Gestational Age
Humans
Hyperbilirubinemia, Neonatal / blood,  etiology
Hyperinsulinism / blood,  etiology*
Hypoglycemia / blood,  etiology
Infant, Newborn
Odds Ratio
Pregnancy
Pregnancy Outcome
ROC Curve
Reference Values
Young Adult
Grant Support
ID/Acronym/Agency:
C06-RR11234/RR/NCRR NIH HHS; HD21410/HD/NICHD NIH HHS; HD27860/HD/NICHD NIH HHS; HD27869/HD/NICHD NIH HHS; HD27915/HD/NICHD NIH HHS; HD27917/HD/NICHD NIH HHS; HD34116/HD/NICHD NIH HHS; HD34136/HD/NICHD NIH HHS; HD34208/HD/NICHD NIH HHS; HD36801/HD/NICHD NIH HHS; HD40485/HD/NICHD NIH HHS; HD40500/HD/NICHD NIH HHS; HD40512/HD/NICHD NIH HHS; HD40544/HD/NICHD NIH HHS; HD40545/HD/NICHD NIH HHS; HD40560/HD/NICHD NIH HHS; HD53097/HD/NICHD NIH HHS; HD53118/HD/NICHD NIH HHS; M01-RR00034/RR/NCRR NIH HHS; M01-RR00080/RR/NCRR NIH HHS; U10 HD053097/HD/NICHD NIH HHS; U10 HD053118/HD/NICHD NIH HHS; UL1 RR024989/RR/NCRR NIH HHS; UL1-RR024989/RR/NCRR NIH HHS; UL1-RR025764/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/C-Peptide
Investigator
Investigator/Affiliation:
G Saade / ; J Moss / ; A Jackson / ; G Hankins / ; A Salazar / ; G Olson Leveno / ; L Moseley / ; J Gold / ; D Bradford / ; L Fay / ; M Garcia / ; F Capellan / ; M Miodovnik / ; F Malone / ; S Bousleiman / ; H Husami / ; V Carmona / ; N Fredericks / ; E Gantioqui / ; B Greenspan / ; M Williams / ; K Anderson / ; P Ashby / ; S McAllister / ; S Quinn / ; F Castinella / ; A Guzman / ; J Steiner / ; J Parker / ; J Sheppard / ; J Tisdale / ; A Northen / ; W Andrews / ; M Carpenter / ; D Catlow / ; D Allard / ; M Seebeck / ; J Tillinghast / ; J Iams / ; F Johnson / ; C Latimer / ; E Weinandy / ; B Maselli / ; K Dorman / ; S Brody / ; S Timlin / ; J Bernhardt / ; M Hoffman / ; E Guzman / ; M Talucci / ; T Grossman / ; C Perez / ; L Zeghibe / ; P Tabangin / ; B Mercer / ; B Stetzer / ; C Milluzzi / ; W Dalton / ; S Pichette / ; M Swain / ; P Meis / ; J White / ; L Gilstrap / ; K Cannon / ; J Martinez / ; D Dusek / ; M Bickus / ; H Birkland / ; M Cotroneo / ; N Cuddy / ; G Norman / ; P Lockhart / ; S Blackwell / ; L Quast / ; P Simon / ; G Mallett / ; L Davis / ; E Lairson / ; C Cromett / ; C Naze / ; M Blaser / ; E Thom / ; J Zachary / ; B Getachew / ; C Cobb / ; L Leuchtenburg / ; S Gilbert / ; S Tolivaisa / ; K Howell /

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.
Next Document:  Resistin-A Novel Feature in the Diagnosis of Sepsis in Premature Neonates.